Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review

被引：40
|
作者：
Schuster, Nathaniel M.
Rapoport, Alan M.
机构：
[1] Center for Pain Medicine, Department of Anesthesia, Critical Care, and Pain Medicine, Wang Ambulatory Care Center, Suite 340, 15 Parkman St, Boston, 02114, MA
[2] Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
来源：
CLINICAL NEUROPHARMACOLOGY | 2017年 / 40卷 / 04期
关键词：
headache treatment; migraine; cluster headache; calcitonin gene-related peptide; monoclonal antibody; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR ANTAGONIST TELCAGEPANT; DOUBLE-BLIND; PREVENTIVE TREATMENT; CGRP RECEPTOR; NEUROPEPTIDE CHANGES; EPISODIC MIGRAINE; EXTRACEREBRAL CIRCULATION; AMG; 334; EFFICACY;
D O I：
10.1097/WNF.0000000000000227
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine. Two of these anti-CGRP monoclonal antibodies are in clinical trials for cluster headache prevention as well. Several other small-molecular CGRP receptor antagonists are in earlier stages of development for acute migraine treatment or prevention. In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache.
引用
收藏
页码：169 / 174
页数：6
相关论文
共 50 条
12345